MSB Trading - Aug 2020 on, page-757

Agreed. The document is not all doom and gloom as some are reading it. It invites further discussion. The 'Draft Points' stated at the end of the document seek evidence via the panel discussion of the potency assay of remestemcel-L. Remember - remestemcel-L is a 'novel' treatment, meaning that the typical measures applied to more traditional drugs, may not be applicable to remestemcel-L and therefore unable to measure potency and product quality. So the panel has been asked to look 'outside the typical square' with remestemcel-L to assess for evidence of potency etc via other measures. So all is not lost. The panel discussion is prudent, scientific process relating to a new and in many ways radical treatment. The fact that the discussion is progressing is in my reading, positive.